# Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

> **NCT04572815** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 116 (actual)

## Conditions studied

- Hematologic and Lymphocytic Disorder
- Hematopoietic and Lymphoid System Neoplasm

## Interventions

- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Ustekinumab

## Key facts

- **NCT ID:** NCT04572815
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-14
- **Primary completion:** 2025-10-27
- **Final completion:** 2027-06-30
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572815, "Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04572815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*